orphan-disease-opportunity-mcp (v1.6.0)
[License: MIT]
[Data License: CC BY 4.0]
[Python 3.10+]
[MCP 2026-07-28]
[SLSA Provenance]
[Live Atlas]
Open Venture & Translational Opportunity Atlas — Read-Only Model Context Protocol (MCP 2026-07-28) Server
Flagship #1: Clonal JAK2 V617F+ Primary Myelofibrosis (jak2-myelofibrosis) • Flagship #2: Reversible Autoimmune Myelofibrosis & Iron/Hepcidin Axis (autoimmune-myelofibrosis) • Web Dossier: https://rare-disease-atlas.github.io
mcp-name: io.github.rare-disease-atlas/orphan-disease-opportunity-mcp
An open, zero-third-party-dependency, 100% read-only Python STDIO + zero-auth Remote Streamable HTTP MCP server (2026-07-28 server/discover + 2025-11-25 initialize + MCP Apps ui://rare-disease-atlas/venture-card) and OpenAPI 3.1 toolkit designed for technical founders (Computational / AI-Bio, Public Health Systems, Venture / Novel Financing) and autonomous AI research agents evaluating high-tractability orphan disease startups, drug-repurposing wedges, 30/60/90-day diligence roadmaps, non-dilutive SBIR/venture-philanthropy grants, and ethical clinical validation guardrails.
Option A: Zero-Install Remote Streamable HTTP MCP (Cloud & Hosted Agents)
Connect immediately over HTTPS with zero local installation and zero API keys:
- Remote MCP Endpoint (
streamable-http): https://api.rare-disease-atlas.workers.dev/mcp
- A2A Peer Agent Card:
https://rare-disease-atlas.github.io/.well-known/agent.json
Option B: Instant 1-Command Local STDIO Execution (uvx or Attested .mcpb)
Run directly from GitHub via uvx with zero external runtime dependencies (pure Python >= 3.10 standard library):
Or download the cryptographically attested orphan-disease-opportunity-mcp.mcpb desktop bundle from GitHub Releases and verify its SLSA build provenance:
Add to Claude Code (1 Command)
Add to Claude Desktop / Cursor / Windsurf / Cline / Antigravity
Paired Myelofibrosis Flagships (jak2-myelofibrosis & autoimmune-myelofibrosis)
Over 7,000 rare diseases carry FDA Orphan Drug Act structural advantages (7-year US market exclusivity, 100% waiver of the $4,682,003 FY2026 PDUFA filing fee, 25% qualified clinical trial tax credit, and N=120–350 pivotal trials). Our Atlas anchors every tool on a paired positive/negative translational control in human bone marrow fibrosis:
- Flagship #1 — Clonal
JAK2 V617F+ Primary Myelofibrosis (jak2-myelofibrosis):
- Single somatic
JAK2 V617F mutation in the JH2 pseudokinase domain drives ~50–60% of Primary Myelofibrosis (ORPHA:824, ~15,000–25,000 US patients).
- All 4 approved Type I
JH1 JAK inhibitors (ruxolitinib, fedratinib, pacritinib, momelotinib) inhibit wild-type JAK2 alongside V617F—causing cytopenias, <15% marrow fibrosis reversal, and 11–23 month median survival post-ruxolitinib failure.
- High-conviction wedges: mutant-selective
JH2 allosteric/PROTAC design (PDB: 6E2Q/8BAK vs 4FVP), Type II persistence breakers, mutant CALR biologics, spatial marrow pathology surrogates, and no-washout RWE trial matching.
- Flagship #2 — Reversible Autoimmune Myelofibrosis (
autoimmune-myelofibrosis, Nature's Positive Control):
JAK2/CALR/MPL-negative lupus/SLE-spectrum marrow fibrosis with dual transfusional + IL-6 -> hepcidin -> ferroportin iron block where human MF-2/MF-3 reticulin fibrosis physically resolves in 74–80% of patients on targeted immunomodulation (Gangat et al., Mayo Clinic 2024).
Exposed Read-Only MCP Capabilities (v1.6.0)
Supports MCP 2026-07-28 (server/discover) and 2025-11-25 (initialize), structured outputSchema + structuredContent, input examples, and MCP Apps UI (ui://rare-disease-atlas/venture-card).
Canonical Read-Only Tools (tools/list & tools/call)
Resources (resources/list & resources/read)
briefing://rare-disease-playbook/jak2-myelofibrosis — Clonal JAK2 V617F+ Myelofibrosis playbook (text/markdown)
briefing://rare-disease-playbook/autoimmune-myelofibrosis — Reversible Autoimmune Myelofibrosis & iron triage playbook (text/markdown)
briefing://rare-disease-playbook/hematology-immunology-expansion — VEXAS, Castleman, Mastocytosis & Telomere cohorts (text/markdown)
briefing://rare-disease-playbook/non-dilutive-grants — Non-dilutive SBIR/ARPA-H/MPNRF/LLS TAP grant stack (text/markdown)
briefing://rare-disease-playbook/validation-ethics — Registries, biobanks & ethical discovery guardrails (text/markdown)
ui://rare-disease-atlas/venture-card — Interactive MCP App HTML card (text/html;profile=mcp-app)
Prompt (prompts/get)
evaluate-rare-disease-venture — Read-only 90-day diligence workflow (founder_background, capital_budget, wet_lab_access).
Verification & Quality Assurance
License